VIM and breast cancer: Vimentin is a type III intermediate filament protein; it regulates the EMT of tumor cells, modulates the migration, invasion, and adhesion of tumor cells, exerts regulatory effects on angiogenesis, and may be a potential target for BC therapy (Chen et al., 2021).